Ascentage Pharma Group International (HK:6855) has released an update.
Ascentage Pharma Group International has announced the grant of 2,059,422 restricted share units (RSUs) to 138 selected employees under their 2018 scheme, which represents about 0.65% of their total issued share capital. This grant, set to vest between 2024 and 2026, is considered by the company’s Board to be fair, reasonable, and in the shareholders’ interests, promising no dilution to existing public shareholders.
For further insights into HK:6855 stock, check out TipRanks’ Stock Analysis page.
